TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $40.67.

TGTX has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. The Goldman Sachs Group increased their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th.

Insider Activity

In related news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.50% of the company’s stock.

Institutional Trading of TG Therapeutics

Large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its holdings in TG Therapeutics by 3.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 80,664 shares of the biopharmaceutical company’s stock valued at $1,435,000 after purchasing an additional 2,871 shares in the last quarter. Creative Planning increased its position in shares of TG Therapeutics by 34.7% during the second quarter. Creative Planning now owns 46,839 shares of the biopharmaceutical company’s stock worth $833,000 after acquiring an additional 12,076 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of TG Therapeutics by 181.9% in the third quarter. SG Americas Securities LLC now owns 23,614 shares of the biopharmaceutical company’s stock worth $552,000 after acquiring an additional 15,238 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in TG Therapeutics by 22.6% in the third quarter. Handelsbanken Fonder AB now owns 49,900 shares of the biopharmaceutical company’s stock valued at $1,167,000 after purchasing an additional 9,200 shares during the last quarter. Finally, Daymark Wealth Partners LLC grew its stake in TG Therapeutics by 73.7% during the 3rd quarter. Daymark Wealth Partners LLC now owns 40,811 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 17,311 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $30.71 on Friday. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84. The firm has a 50 day simple moving average of $31.15 and a 200-day simple moving average of $27.31. The firm has a market cap of $4.78 billion, a PE ratio of -307.07 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.